Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Recruiting · NCT05388149 · Registry updated 2025-01-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-01-31 | NCT05388149 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Health Network, Toronto | 417 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Health Network: Princess Margaret Cancer Centre | Toronto | Canada | 1 |